AAME vs DRUG
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 26, 2026
AAME
DRUG
Investment Advisor Scores
DRUG
AI Analyst Insights
Detailed Metrics Comparison
| Metric | AAME | DRUG | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 7.391 | 0 | Tie |
| PEG Ratio | 2.4344 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 4.8% | 0.0% | AAME |
| Earnings Growth | -59.7% | 0.0% | DRUG |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 35.5/100 | 46.4/100 | DRUG |
| Profit Margin | 2.9% | 0.0% | AAME |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | AVOID NEW MONEY | HOLD | DRUG |
Relative Price Performance (Last 90 Days)
Current Technical Phase
AAME
NeutralMixed signals - no dominant trend phase, RSI 47
DRUG
MarkdownPrice below a falling SMA50 (slope -13.6%), weak momentum, RSI 45
Fundamentals Snapshot
| Metric | AAME | DRUG |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 7.4 | -6.5 |
| Trailing P/E | 5.1 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.0% |
| Gross Margin | 0.1% | — |
| Operating Margin | 0.0% | 0.0% |
| EPS | 0.31 | -2.05 |
| Dividend Yield | — | — |